{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anaplastic+Lymphoma+Kinase&page=2",
    "query": {
      "condition": "Anaplastic Lymphoma Kinase",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anaplastic+Lymphoma+Kinase&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T23:23:21.356Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02201992",
      "title": "Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ALK Gene Rearrangement",
        "ALK Gene Translocation",
        "ALK Positive",
        "Stage IB Non-Small Cell Lung Carcinoma AJCC v7",
        "Stage II Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIA Non-Small Cell Lung Carcinoma AJCC v7",
        "Stage IIB Non-Small Cell Lung Carcinoma AJCC v7",
        "Stage IIIA Non-Small Cell Lung Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2015-03-23",
      "completion_date": "2036-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-19",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 1613,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02201992"
    },
    {
      "nct_id": "NCT05142189",
      "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "BNT116",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "BNT316",
          "type": "BIOLOGICAL"
        },
        {
          "name": "anti-B7-H3 antibody conjugated to topoisomerase I inhibitor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "anti-HER3 antibody conjugated to topoisomerase I inhibitor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bispecific antibody for PD-L1 and VEGF-A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Osimertinib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALK-inhibitor or RET-inhibitor",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2022-06-17",
      "completion_date": "2031-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 5,
      "location_summary": "Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05142189"
    },
    {
      "nct_id": "NCT02927340",
      "title": "A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2016-10",
      "completion_date": "2023-05",
      "has_results": false,
      "last_update_posted_date": "2021-03-09",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02927340"
    },
    {
      "nct_id": "NCT02048488",
      "title": "A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors",
        "Lymphomas"
      ],
      "interventions": [
        {
          "name": "TSR-011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2012-10",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2019-03-26",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 6,
      "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 3 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02048488"
    },
    {
      "nct_id": "NCT03546894",
      "title": "A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anaplastic Lymphoma Kinase-positive",
        "Carcinoma Non-small-cell Lung"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        },
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Ceritinib",
          "type": "DRUG"
        },
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "Any FDA Approved ALK Inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2018-07-23",
      "completion_date": "2023-02-13",
      "has_results": false,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 1,
      "location_summary": "Maynard, Massachusetts",
      "locations": [
        {
          "city": "Maynard",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03546894"
    },
    {
      "nct_id": "NCT03052608",
      "title": "A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Lorlatinib",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 296,
      "start_date": "2017-04-27",
      "completion_date": "2028-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 34,
      "location_summary": "Altamonte Springs, Florida • Brandon, Florida • Clearwater, Florida + 23 more",
      "locations": [
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03052608"
    },
    {
      "nct_id": "NCT06256484",
      "title": "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory B-cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "ATA3219",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atara Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 1,
      "start_date": "2024-09-06",
      "completion_date": "2025-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Louisville, Kentucky • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06256484"
    },
    {
      "nct_id": "NCT00504205",
      "title": "MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "multitargeted receptor tyrosine kinase inhibitor MP470",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2007-05",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2013-08-02",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • San Antonio, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00504205"
    },
    {
      "nct_id": "NCT05502237",
      "title": "Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1021,
      "start_date": "2022-10-12",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 11,
      "location_summary": "Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Asheville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05502237"
    },
    {
      "nct_id": "NCT01154140",
      "title": "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Squamous Lung Cancer"
      ],
      "interventions": [
        {
          "name": "treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 343,
      "start_date": "2011-01-13",
      "completion_date": "2016-11-30",
      "has_results": true,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-06-25T23:23:21.356Z",
      "location_count": 84,
      "location_summary": "Beverly Hills, California • Fontana, California • Loma Linda, California + 53 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fontana",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01154140"
    }
  ]
}